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Recent advances in social science surveys include collection of biological sam-
ples. Although biomarkers offer a large potential for social science and eco-
nomic research, they impose a number of statistical challenges, often being
distributed asymmetrically with heavy tails. Using data from the UK House-
hold Panel Survey, we illustrate the comparative performance of a set of flexi-
ble parametric distributions, which allow for a wide range of skewness and
kurtosis: the four‐parameter generalized beta of the second kind (GB2), the
three‐parameter generalized gamma, and their three‐, two‐, or one‐parameter
nested and limiting cases. Commonly used blood‐based biomarkers for inflam-
mation, diabetes, cholesterol, and stress‐related hormones are modelled.
Although some of the three‐parameter distributions nested within the GB2 out-
perform the latter for most of the biomarkers considered, the GB2 can be used
as a guide for choosing among competing parametric distributions for bio-
markers. Going “beyond the mean” to estimate tail probabilities, we find that
GB2 performs fairly well with some disparities at the very high levels of
to perform worse than almost all the flexible distributions.
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Recent developments in social surveys include the integration of biomarkers and self‐reported health measures. Bio-
markers are objectively measured indicators of normal biological or pathogenic processes and, as such, offer at least
two key advances over self‐report health. First, biomarkers are not subject to reporting bias; given evidence for socio‐
economic‐related reporting bias in health, biomarkers offer a significant advantage in socioeconomic inequalities
research (Bago d'Uva, O'Donnell, & van Doorslaer, 2008; Carrieri & Jones, 2017). Second, biomarkers can contribute
to our understanding of the underlying biological factors through which socioeconomic conditions get “under the skin”
(e.g., thought stress‐related physiological responses) and the role of socioeconomic exposures at earlier pre‐symptomatic
health states (Davillas, Benzeval, & Kumari, 2017; Jürges, Kruk, & Reinhold, 2013).- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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2 DAVILLAS AND JONESA growing literature analyses the effect of socioeconomic position on the conditional mean of biomarkers
(e.g., Davillas et al., 2017, Jürges et al., 2013). However, biomarkers create several statistical modeling challenges as they
often have skewed distributions with heavy tails (Jones, 2017). Furthermore, errors are likely to be heteroskedastic and
responses to covariates may be nonlinear. Existing studies have estimated linear regression models using ordinary least
squares (OLS) on raw or log‐transformed biomarkers (Jürges et al., 2013) and alternative inherently nonlinear specifi-
cations, such as the generalized linear models (Davillas et al., 2017). Although OLS on log rather than on levels might
improve performance by reducing skewness, re‐transformation to the raw scale—as health policymakers require—is
highly challenging, requiring knowledge of the degree and form of heteroscedasticity (Jones, Lomas, & Rice, 2014).
Although the generalized linear model family deals with heteroskedasticity, it fails to explicitly account for skewness
and kurtosis, imposing potential bias and efficiency losses (Jones et al., 2014).
Our paper contributes to the literature on modeling biomarkers by comparing the performance of a set of more flex-
ible parametric distributions, the generalized beta of the second kind (GB2), the generalized gamma (GG), and their
nine nested and limiting cases; we use nationally representative UK data on commonly used blood‐based biomarkers
for inflammation, diabetes, cholesterol, and stress‐related hormones (Carrieri & Jones, 2017). The GG and GB2 allow
for a wide range of skewness and kurtosis to better accommodate the biomarker data generation processes; these distri-
butions have been proposed for fitting heavily skewed outcomes (e.g., health care costs; Jones et al., 2014), to which bio-
markers share similar distributional features. For comparison purposes, linear regression models using OLS are also
estimated. Given that different biomarkers exhibit different distributions, identifying GB2 as a discriminatory tool
among competing distributions might be useful for health researchers. Going “beyond the mean”, we also explore to
what extent the GB2 and its nested cases that exerted the best goodness of fit (for each biomarker) regarding the whole
distribution also perform well to predict tail probabilities.2 | METHODS
The three‐parameter GG distribution has been introduced as robust alternative to common estimation techniques for
asymmetric data (Manning, Basu, & Mullahy, 2005). More recently, Jones, Lomas, and Rice (2014) have suggested
adding further flexibility based on the four‐parameter GB2 distribution. GB2 allows for a wider range of skewness
and kurtosis, choosing among its several special or nested cases, whereas GB2's extra flexibility may also enhance per-
formance (Jones et al., 2014).
The GG distribution has a density function and conditional expectation that take the form:
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where γ = |κ|−2, z = sign (κ){ln(y) − μ}, u = γ exp (|κ|z), μ = x′β, and Γ(.) is the gamma function. Parameters κ and σ are
the shape parameters (Manning et al., 2005). The GG nests the gamma (κ = σ), Weibull (κ = 1), exponential
(κ = 1,σ = 1), and lognormal (κ = 0) distributions.
The four‐parameter GB2 distribution adds further flexibility and has a probability density function and conditional
mean of
f y; a; b; p; qð Þ ¼ ay
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and
FIGURE 1 Distribution of biomarkers and quantile‐normal (Q‐N) plots. DHEAS: dehydroepiandrosterone sulfate; HbA1c: glycated
hemoglobin [Colour figure can be viewed at wileyonlinelibrary.com]
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where b = exp (x′β) and B(.) and Γ(.) are the beta and gamma functions (Jones et al., 2014). Parameter a influences
kurtosis and p and q the skewness of the distribution. We also estimate the nested and limiting cases of GB2: the
three‐parameter beta of the second kind (B2) [a = 1], Singh–Maddala (SM) [p = 1], and Dagum [q = 1]; the two‐param-
eter Fisk [p = q = 1], and Lomax [p = a = 1]. GG itself is also a limiting case of the GB2, where b = q1/aβ and q → ∞
(Jones et al., 2014). We also estimate linear regression models using OLS.
The restrictions imposed by each of the special and limiting cases within the GG and GB2 are evaluated using Wald
and likelihood ratio (LR) tests. To assess the comparative performance of beta‐ with gamma‐family distributions (being
limited cases and not a linear restriction of a parameter), we compare Akaike (AIC) and Bayesian (BIC) information
criteria across all models (Jones et al., 2014).
3 | DATA
The UK Household Panel Study (UKHLS) is a large, nationally representative UK study. At UKHLS Wave 2, partici-
pants from its predecessor, the British Household Panel Survey, were also incorporated. Non‐fasted blood samples were
collected, after the UKHLS Wave 2 interview for the original UKHLS respondents and, at Wave 3, for the British House-
hold Panel Survey sample. Pooling biomarker data from UKHLS Waves 2 and 3 (2010–2013) resulted in a potential sam-
ple of 13,107 respondents.
Four biomarkers are used. Fibrinogen is an inflammatory biomarker, with higher values linked to cardiovascular
morbidity and all‐cause mortality risks (Davillas et al., 2017). Glycated hemoglobin (HbA1c) is a diagnostic biomarker
for diabetes. The ratio of total cholesterol to high‐density lipoprotein cholesterol is used as a marker for fatty substances
in the blood. Dehydroepiandrosterone sulfate (DHEAS) is a steroid hormone and one of the mechanisms through which
psychosocial stressors might affect health (Vie, Hufthammer, Holmen, Meland, & Breidablik, 2014). Given our focus on
the comparative performance of parametric distributions regarding goodness of fit, rather than explore potential effects
TABLE 1 LR and Wald tests (p‐values) for special cases of the GB2 and GG
Fibrinogen HbA1c Cholesterol ratio DHEAS
LR Wald LR Wald LR Wald LR Wald
GB2 versus …
B2 0.000 0.000 0.000 0.000 0.247 0.193 0.000 0.000
SM 0.208 0.236 0.000 0.000 0.000 0.188 0.703 0.710
Dagum 0.004 0.013 0.000 0.000 0.000 0.020 0.000 0.000
Fisk 0.002 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Lomax 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
GG versus …
Gamma 0.000 0.024 0.000 0.000 0.000 0.000 0.000 0.000
Lognormal 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Weibull 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Exponential 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Note. B2: beta of the second kind; DHEAS: dehydroepiandrosterone sulfate; LR: likelihood ratio; GB2: generalized beta of the second kind; GG: generalized
gamma; HbA1c: glycated hemoglobin; SM: Singh–Maddala. For each biomarker, bold p‐values highlight those models that we are not able to reject the null
hypothesis of restrictions being valid, according to both the LR and Wald tests, compared to the GB2 or GG models.
TABLE 2 AIC and BIC for each model
Fibrinogen Hba1c Cholesterol ratio DHEAS
AIC BIC AIC BIC AIC BIC AIC BIC
GB2 20,866 20,948 72,138 72,219 39,175 39,257 53,800 53,889
B2 21,221 21,296 76,134 76,371 39,173 39,249 53,897 53,979
SM 20,865 20,939 72,329 72,404 39,432 39,506 53,798 53,880
Dagum 20,872 20,947 72,927 73,001 39,315 39,390 53,855 53,937
Fisk 20,883 20,950 73,563 73,629 39,482 39,549 54,149 54,223
Lomax 51,843 51,910 112,182 112,249 59,542 59,624 61,959 62,040
GG 21,204 21,278 74,986 75,060 39,180 39,270 53,927 54,016
Lognormal 21,502 21,569 77,305 77,372 39,306 39,373 54,407 54,482
Gamma 21,219 21,287 79,049 79,116 39,867 39,934 53,942 54,016
Weibull 22,804 22,871 88,676 88,743 42,443 42,518 54,640 54,715
Exponential 51,841 51,900 112,180 112,239 59,540 59,615 61,957 62,031
OLS 21,500 21,558 84,119 84,178 42,875 42,950 58,371 58,446
Note. AIC: Akaike information criteria; BIC: Bayesian information criteria; B2: beta of the second kind; DHEAS: dehydroepiandrosterone sulfate; GB2: gener-
alized beta of the second kind; GG: generalized gamma; HbA1c: glycated hemoglobin; OLS: ordinary least squares; SM: Singh–Maddala. For each biomarker,
bold values highlight those models that exhibit the best performance according to AIC and BIC.
4 DAVILLAS AND JONESfrom covariates, a parsimonious set of covariates is used: polynomials of age (cubic or quartic depending on the bio-
marker used), gender, and their interactions to allow for flexible gender effects (Figure A1).14 | RESULTS
Figure 1 presents the distribution of biomarkers (descriptive statistics in Table A1). Fibrinogen has a symmetric distri-
bution but with fat tails (Figure 1). HbA1c is much more skewed (skewness statistic of 4.2 compared with zero for nor-
mal data) with long right‐hand tails and excess kurtosis (31.15 vs. 3 for normal data; Table A1). The cholesterol ratio and
DHEAS also exhibit long right‐hand tails and high kurtosis.
Table 1 contains restriction tests for the nested and limiting cases within the GG and GB2. Across all biomarkers, we
find no evidence in support of any of the special cases within the GG distribution. For fibrinogen, we are unable to reject
the null hypothesis of the restriction being valid for the SM model. Our results for HbA1c do not support any of the
nested distributions. For the cholesterol ratio, both the LR and Wald tests favor the B2 distribution. Although the Wald1The limited number of covariates may also alleviate concerns that, for less parsimonious specifications, the best specification for each model need to
be compared rather than using the same covariates (Jones et al., 2014). However, the relative performance of our models (Table 2) remained the same
in the case of no covariates.
FIGURE 2 Actual versus fitted tail probabilities. DHEAS: dehydroepiandrosterone sulfate; HbA1c: glycated hemoglobin [Colour figure
can be viewed at wileyonlinelibrary.com]
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6 DAVILLAS AND JONEStest also fails to reject the null hypothesis for SM, this is not confirmed by the LR test; this disparity reflects the wide
confidence intervals for GB2's p parameter (which include both 1, satisfying the SM restriction, and 0; Table A2).
Our results for DHEAS favor the SM distribution.
Table 2 shows that AIC and BIC results are in accordance with the tests of Table 1. For all biomarkers, linear regres-
sions estimated by OLS perform worse than each of the four‐ and three‐parameter and most of the more parsimonious
distributions. For fibrinogen, GB2 and SM perform best according to AIC and BIC criteria, with the latter showing the
best performance. GB2 outperforms all the competing distributions regarding HbA1c. Although the B2 and SM distri-
butions exhibit the best performance for the cholesterol ratio and DHEAS, GB2 is ranked the second best.
Figure 2 presents the conditional tail probabilities (at k equal to 10th, 25th, 50th, 75th, and 90th quantile) and spike
plots of the actual‐fitted difference (bias) for the GB2 distribution, and its nested cases exerted the best performance for
each biomarker (Table 2). Specifically, 20‐quantiles of the fitted values from these models are used to split the sample to
calculate within‐quantiles means of actual [P(y > k)] and predicted [P(y > k|X)] probabilities.
There are limited differences in the predictive ability of the more parsimonious distributions compared with GB2,
confirming previous evidence that a flexible distribution is not a substitute for finding the correct distribution (Jones
et al., 2014). GB2 performs reasonably well at predicting tail probabilities, although there are some disparities at the very
high fibrinogen levels (90th quantile) and HbA1c above the pre‐diabetes threshold (HbA1c ≥ 42).5 | CONCLUSION
We illustrate the comparative performance of a set of more flexible parametric distributions: the GB2, GG, and their
nested and limiting cases for a set of biomarkers. Although some of the three‐parameter distributions nested within
the GB2 (mainly the B2 and SM) outperform the latter in most of the biomarkers considered, GB2 can be used as a guide
for choosing among competing distributions; a potentially useful message for applied researchers given that different
biomarkers follow different distributions. The linear models estimated by OLS are dominated by almost all the compet-
itive models. GB2 performs well at predicting biomarkers' tail probabilities, although with some disparities at the very
high levels of fibrinogen and HbA1c.CONFLICT OF INTEREST
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Fibrinogen (g/L) 2.79 2.70 0.59 0.47 3.82 0.40 5.50 12,811
HbA1c (mmol/mol) 37.25 36.00 8.19 4.17 31.15 12 133.0 12,153
Cholesterol ratio 3.74 3.46 1.36 1.42 6.43 1.16 13.67 12,865
DHEAS (μmol/L) 4.62 3.80 3.24 1.29 5.11 0.20 25.30 12,809
Note. DHEAS: dehydroepiandrosterone sulfate; HbA1c: glycated hemoglobin.
FIGURE A1 Quantile–quantile plots of the biomarkers by gender [Colour figure can be viewed at wileyonlinelibrary.com]
TABLE A2 Estimated parameters from the GB2 and the GG models
Biomarker GB2 GG
α p q κ Ln(σ)
Fibrinogen 7.892 [7.017, 8.767] 1.104 [0.933, 1.275] 1.299 [1.063, 1.535] 0.267 [0.209, 0.326] −1.606 [−1.621, −1.592]
HbA1c 42.986 [36.674, 49.298] 0.348 [0.287, 0.410] 0.198 [0.167, 0.230] −0.461 [−0.555, −0.368] −1.970 [−2.017, −1.924]
Cholesterol ratio 1.442 [0.777, 2.108] 23.345 [−9.920, 56.612] 6.611 [1.761, 11.463] −0.246 [−0.290, −0.200] −1.169 [−1.183, −1.157]
DHEAS 2.538 [2.202, 2.873] 1.036 [0.846, 1.225] 2.316 [1.717, 2.915] 0.446 [0.396, 0.495] −0.615 [−0.631, −0.599]
Note. DHEAS: dehydroepiandrosterone sulfate; GB2: generalized beta of the second kind; GG: generalized gamma; HbA1c: glycated hemoglobin.
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